This study is looking at how the treatment Lu-177 PSMA (also known as Pluvicto) works in patients who have prostate cancer and also have kidney problems or issues with their bone marrow. Researchers want to understand how much of the Lu-177 PSMA medicine is absorbed by tumors and other organs in these patients. You might be able to join if you are approved for Pluvicto therapy and have certain levels of kidney (renal) complications or compromised bone marrow function, which means your white blood cell (WBC) or platelet counts are outside a normal range. The main goal is to check the safety and any side effects (adverse events) of the treatment over about one year. The study is currently unclear on its recruitment status and plans to enroll 25 men.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 25 participants.

What's involved

You will receive Lu-177 PSMA through an IV and undergo SPECT/CT scans. The study will monitor your safety and side effects for about one year.

Compensation

Not stated in the trial record.

Follow-up

Your safety and adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.